Journal Article


Martin Clynes
Verena Amberger-Murphy
Mary Heenan
Laura Breen



inhibitory concentration 50 physiology pharmacology metabolism humans drug resistance neoplasm carboplatin tp53 protein human cell line tumor genetics drug therapy tumor suppressor protein p53 drug resistance multiple biosynthesis plasmids transfection doxorubicin paclitaxel lung neoplasms

Investigation of the role of p53 in chemotherapy resistance of lung cancer cell lines. (2007)

Abstract p53 is a tumour suppressor gene, which is mutated in more than half of all tumours. Most chemotherapeutic drugs cause DNA damage, which is sensed by p53; the cell can then try to repair the damage or induce cell suicide. If the p53 machinery is defective, effective chemotherapy is made more difficult. Wild-type p53 was transfected into lung cancer cell lines with different p53 status. The transfected cells were tested for changes in sensitivity to a range of chemotherapeutic agents. We observed only modest changes in the sensitivity to the chemotherapeutic agents adriamycin, taxol and carboplatin in the transfected cells lines. p53 protein was detected in a transfected clone of the cell line H1299, whose parent cells are p53 null. However, the protein did not accumulate after DNA damage, suggesting that this cell line utilises alternative pathways for responding to stress, and no longer has a functional p53 pathway. The results suggest that introduction of wild-type p53 alone is not sufficient to substantially alter the sensitivity of a cell line to a given chemotherapeutic agent.
Collections Ireland -> Dublin City University -> PubMed

Full list of authors on original publication

Martin Clynes, Verena Amberger-Murphy, Mary Heenan, Laura Breen

Experts in our system

Martin Clynes
Dublin City University
Total Publications: 209
Laura Breen
Dublin City University
Total Publications: 11